NMIC Bulletin Vol.31 No.1 2025. An update on valproate

4 November, 2025

  • There are known teratogenic and neurodevelopmental risk associated with the maternal use of valproate
  • HPRA pharmacovigilance updates highlight the safety concerns, restrictions and contraindications associated with the prescribing and use of valproate in girls and women of childbearing potential
  • Due to the potential increased risk of neurodevelopmental disorders in children born to men treated with valproate during the three months before conception ,the EMA has also recommended precautionary measures for male patients
  • HPRA valproate risk minimisation measures are tailored to the specific responsibilities and roles of each Health Care Professional (HCP)

Click here to view.